Floatz logo

56 assets in Skin Squamous Cell Carcinoma

Therapeutic assets addressing Skin Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Prednisone
Skin Squamous Cell Carcinoma
Dana-Farber Cancer InstituteP4BB (67)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Skin Squamous Cell Carcinoma
Regeneron PharmaceuticalsP3BB (66)
Sirolimus
Skin Squamous Cell Carcinoma
Dana-Farber Cancer InstituteP4BB (66)
Everolimus
Skin Squamous Cell Carcinoma
Dana-Farber Cancer InstituteP4BB (64)
Cyclophosphamide
Skin Squamous Cell Carcinoma
Merck Sharp & Dohme LLCP2B (63)
Nivolumab
Skin Squamous Cell Carcinoma
Fred Hutchinson Cancer CenterP2B (63)
Pembrolizumab
Skin Squamous Cell Carcinoma
Merck Sharp & Dohme LLCP2B (62)
Lenvatinib
Skin Squamous Cell Carcinoma
Merck Sharp & Dohme LLCP2B (61)
Anti-Pd-L1 Monoclonal Antibody Ck-301
Skin Squamous Cell Carcinoma
Dana-Farber Cancer InstituteP4B (58)
Fludarabine
Skin Squamous Cell Carcinoma
Genocea Biosciences, Inc.P2B (58)
Favezelimab
Skin Squamous Cell Carcinoma
Merck Sharp & Dohme LLCP2B (57)
Carboplatin
Skin Squamous Cell Carcinoma
Rapa Therapeutics LLCP1/2CCC (54)
Docetaxel
Skin Squamous Cell Carcinoma
Hummingbird BioscienceP1/2CCC (54)
Ipilimumab
Skin Squamous Cell Carcinoma
National Cancer Institute (NCI)P1/2CCC (54)
Hydrogen Peroxide 30 % Topical
Skin Squamous Cell Carcinoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sP2CCC (53)
Ivonescimab
Skin Squamous Cell Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
TIL
Skin Squamous Cell Carcinoma
Udai KammulaP2CCC (53)
Atezolizumab
Skin Squamous Cell Carcinoma
KaliVir ImmunotherapeuticsP1/2CCC (50)
Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201
Skin Squamous Cell Carcinoma
Rapa Therapeutics LLCP1/2CCC (48)
azd6750
Skin Squamous Cell Carcinoma
AstraZenecaP1/2CCC (48)
Cetuximab
Skin Squamous Cell Carcinoma
Hummingbird BioscienceP1/2CCC (48)
Cetuximab Sarotalocan
Skin Squamous Cell Carcinoma
Rakuten Medical, Inc.P1/2CCC (48)
Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-31*01 (89.9%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg1*01 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (85.3%)-Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa
Skin Squamous Cell Carcinoma
Hummingbird BioscienceP1/2CCC (48)
jk08
Skin Squamous Cell Carcinoma
Salubris Biotherapeutics IncP1/2CCC (48)
Montanide Isa 51
Skin Squamous Cell Carcinoma
Roswell Park Cancer InstituteP1/2CCC (48)
n17350
Skin Squamous Cell Carcinoma
Onchilles Pharma IncP1/2CCC (48)
Oncolytic Virus Rp1
Skin Squamous Cell Carcinoma
Replimune, Inc.P1/2CCC (48)
Recombinant Human Egf-Rp64K
Skin Squamous Cell Carcinoma
Roswell Park Cancer InstituteP1/2CCC (48)
Rilvegostomig
Skin Squamous Cell Carcinoma
AstraZenecaP1/2CCC (48)
Sargramostim
Skin Squamous Cell Carcinoma
Mayo ClinicP1/2CCC (48)
Fruquintinib
Skin Squamous Cell Carcinoma
Immunitas TherapeuticsP1/2CC (45)
Idp-001
Skin Squamous Cell Carcinoma
InduPro, Inc.P1/2CC (45)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Klrb1 (Killer Cell Lectin Like Receptor B1, Nkr-P1A, Natural Killer Cell Surface Protein P1A, Clec5B, Cd161)], Homo Sapiens Monoclonal Antibody; Gamma1 Heavy Chain Homo Sapiens (1-450) [Vh (Homo Sapiens Ighv3-23*01 (96.9%) -(Ighd) -Ighj4*01 (85.7%), Q120>R (113), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, G1V29 Ch2 A84.4 (Ch1 K120 (218) (122-219), Hinge 1-15 (220-234), Ch2 G1V29 Ch2 N84.4>A (301) (235-344), Ch3 D12 (360), L14 (362) (345-449), Chs K2>Del (450)) (122-450)], (224-214')-Disulfide With Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (94.7%) -Igkj4*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; Dimer (230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1 Lacking The Glutamine Synthetase (Gs-Ko) Gene, Non-Glycosylated
Skin Squamous Cell Carcinoma
Immunitas TherapeuticsP1/2CC (45)
Mdna11
Skin Squamous Cell Carcinoma
Medicenna Therapeutics, Inc.P1/2CC (45)
Vidutolimod
Skin Squamous Cell Carcinoma
Regeneron PharmaceuticalsP2CC (45)
Bbi-355
Skin Squamous Cell Carcinoma
Boundless Bio, Inc.P1CC (43)
Bbi-825
Skin Squamous Cell Carcinoma
Boundless Bio, Inc.P1CC (43)
Cis-Diamminedichloroplatinum Ii
Skin Squamous Cell Carcinoma
Seagen, a wholly owned subsidiary of PfizerP1CC (43)
Evolve104
Skin Squamous Cell Carcinoma
EvolveImmune United, IncP1CC (43)
Futibatinib
Skin Squamous Cell Carcinoma
Boundless Bio, Inc.P1CC (43)
Kup-101A
Skin Squamous Cell Carcinoma
Kupando GmbHP1CC (43)
ph-762
Skin Squamous Cell Carcinoma
Phio Pharmaceuticals Inc.P1CC (43)
r-5780
Skin Squamous Cell Carcinoma
Rise Therapeutics LLCP1CC (43)
Sigvotatug Vedotin
Skin Squamous Cell Carcinoma
Seagen, a wholly owned subsidiary of PfizerP1CC (43)
Sonidegib
Skin Squamous Cell Carcinoma
Mayo ClinicP1CC (43)
Tacrolimus
Skin Squamous Cell Carcinoma
National Cancer Institute (NCI)P1CC (43)
vet3-tgi
Skin Squamous Cell Carcinoma
KaliVir ImmunotherapeuticsP1CC (43)
Cdx 1140
Skin Squamous Cell Carcinoma
University of Southern CaliforniaP1CC (41)
Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mus Musculus Clone Bca101 ?1-Chain), Disulfide With Human-Mus Musculus Clone Bca101 ?-Chain Fusion Protein With Peptide Linker (Ggggs)3 Fusion Protein With 23-159-Transforming Growth Factor ? Receptor Tgfbr2 (Human), Dimer
Skin Squamous Cell Carcinoma
Bicara TherapeuticsP1CC (41)
Mem-288 Intratumoral
Skin Squamous Cell Carcinoma
Memgen, Inc.P1CC (41)
Showing 1 to 50 of 56 assets
PreviousPage 1 of 2Next